Actualités Tetra Bio Pharma Inc - TBP | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Tetra Bio-Pharma Announces Listing to OTCPink Market

Tetra Bio-Pharma Announces Listing to OTCPink Market PR Newswire MONTREAL, Feb. 10, 2023 MONTREAL, Feb. 10...

REDUVO™ Marketing Approval on the Right Path

REDUVO™ Marketing Approval on the Right Path PR Newswire MONTREAL, Dec. 22, 2022 Second Clarifax...

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir PR...

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 PR Newswire MONTREAL...

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission PR Newswire MONTREAL, Nov. 18, 2022...

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean PR Newswire OTTAWA, ON, Oct...

Tetra and Prepaire Jointly Apply to BARDA for Funding

Tetra and Prepaire Jointly Apply to BARDA for Funding PR Newswire OTTAWA, ON, Oct. 11, 2022 Companies jointly...

Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean PR...

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients PR...

Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean

Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean PR Newswire OTTAWA, ON, Aug. 11, 2022...

Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral...

Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a...

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update PR Newswire OTTAWA, ON, June...

Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting PR Newswire OTTAWA, ON...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tetra Bio Pharma Inc (TBP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TBP Actualités

Tetra Bio-Pharma Announces Listing to OTCPink Market

REDUVO™ Marketing Approval on the Right Path

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean

Tetra and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean

Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tetra Bio Pharma Inc (TBP) Actualités

Tetra Bio Pharma Inc (TBP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TBP Actualités

Tetra Bio-Pharma Announces Listing to OTCPink Market

REDUVO™ Marketing Approval on the Right Path

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean

Tetra and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean

Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités